Dr Katrin Kramer
| Position | Research Fellow |
|---|---|
| Department | Department of Pathology (DSM) |
| Qualifications | BSc PhD |
| Research summary | Immune therapies for cancer |
Research
My research interest focusses on the development of cancer immunotherapies. I am especially interested in understanding how the delivery form of immunotherapies influences their efficacy and how novel therapies can be combined to induce an effective anti-cancer immune response.During my PhD at the School of Pharmacy, University of Otago, I worked on generating and comparing different linking mechanisms between cancer antigen and vaccine adjuvants and how they influence the generation of anti-tumour immune responses. My current project as a Postdoctoral Fellow in the Department of Pathology focuses on developing an immunotherapy for breast cancer. For this I use virus-like particles (VLP) delivering tumour antigens in order to prime immune cells to selectively recognise and destroy cancer cells while sparing healthy cells. Furthermore I work on understanding how successful immunotherapies are in a diverse patient population and whether specific patient groups benefit from different treatment combinations.
Publications
Kramer, K., Al-Barwani, F., Baird, M. A., Young, V. L., Larsen, D. S., Ward, V. K., & Young, S. L. (2019). Functionalisation of virus-like particles enhances antitumour immune responses. Journal of Immunology Research, 2019, 5364632. doi: 10.1155/2019/5364632
Kramer, K., Young, S. L., & Walker, G. F. (2019). Data on the uptake of reducible antigen-adjuvant conjugates by dendritic cells [Data article]. Data in Brief. Advance online publication. doi: 10.1016/j.dib.2019.103759
Kramer, K., Shields, N. J., Poppe, V., Young, S. L., & Walker, G. F. (2017). Intracellular cleavable CpG oligodeoxynucleotide-antigen conjugate enhances anti-tumor immunity. Molecular Therapy, 25(1), 62-70. doi: 10.1016/j.ymthe.2016.10.001
Grant, M. L., Shields, N., Neumann, S., Kramer, K., Bonato, A., Jackson, C., Baird, M. A., & Young, S. L. (2017). Combining dendritic cells and B cells for presentation of oxidised tumour antigens to CD8+ T cells. Clinical & Translational Immunology, 6(7), e149. doi: 10.1038/cti.2017.28
Kramer, K., Young, S. L., & Walker, G. F. (2017). Comparative study of 5′- and 3′-linked CpG–antigen conjugates for the induction of cellular immune responses. ACS Omega, 2(1), 227-235. doi: 10.1021/acsomega.6b00368
Journal - Research Article
Kramer, K., Al-Barwani, F., Baird, M. A., Young, V. L., Larsen, D. S., Ward, V. K., & Young, S. L. (2019). Functionalisation of virus-like particles enhances antitumour immune responses. Journal of Immunology Research, 2019, 5364632. doi: 10.1155/2019/5364632
Kramer, K., Shields, N. J., Poppe, V., Young, S. L., & Walker, G. F. (2017). Intracellular cleavable CpG oligodeoxynucleotide-antigen conjugate enhances anti-tumor immunity. Molecular Therapy, 25(1), 62-70. doi: 10.1016/j.ymthe.2016.10.001
Kramer, K., Young, S. L., & Walker, G. F. (2017). Comparative study of 5′- and 3′-linked CpG–antigen conjugates for the induction of cellular immune responses. ACS Omega, 2(1), 227-235. doi: 10.1021/acsomega.6b00368
Grant, M. L., Shields, N., Neumann, S., Kramer, K., Bonato, A., Jackson, C., Baird, M. A., & Young, S. L. (2017). Combining dendritic cells and B cells for presentation of oxidised tumour antigens to CD8+ T cells. Clinical & Translational Immunology, 6(7), e149. doi: 10.1038/cti.2017.28
Journal - Research Other
Kramer, K., Young, S. L., & Walker, G. F. (2019). Data on the uptake of reducible antigen-adjuvant conjugates by dendritic cells [Data article]. Data in Brief. Advance online publication. doi: 10.1016/j.dib.2019.103759
